UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJYGet Rating) was the recipient of a large drop in short interest in April. As of April 30th, there was short interest totalling 2,200 shares, a drop of 68.1% from the April 15th total of 6,900 shares. Based on an average daily volume of 25,300 shares, the days-to-cover ratio is presently 0.1 days.

UCBJY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft cut UCB from a “buy” rating to a “hold” rating in a research report on Monday, January 24th. Morgan Stanley raised UCB from an “equal weight” rating to an “overweight” rating in a research note on Thursday, March 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, UCB presently has a consensus rating of “Hold” and a consensus price target of $52.84.

Shares of OTCMKTS:UCBJY opened at $45.71 on Friday. The stock’s 50-day moving average price is $57.56 and its two-hundred day moving average price is $55.43. UCB has a 12-month low of $44.92 and a 12-month high of $63.94.

The company also recently disclosed a dividend, which will be paid on Wednesday, May 18th. Stockholders of record on Monday, May 2nd will be paid a $0.4413 dividend. This represents a dividend yield of 0.74%. The ex-dividend date of this dividend is Friday, April 29th.

UCB Company Profile (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.